Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.

Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...

Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an ...

Shares of Roivant, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading. However, ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Progyny (PGNY – Research Report) and Roivant ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

"This is another example of Roivant's ability to offer creative win-win collaborations. We are able to meet Organon's structural objectives and to create a transaction that is very attractive to both ...

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

Roivant Sciences Ltd. (NASDAQ:ROIV), a pharmaceutical company, announced the results of its Annual General Meeting held on Monday. Shareholders voted on several key proposals, including the re ...